This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease.
The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.
As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. View the study.
This October, we gather for the largest and most innovative cardiometabolic event, honoring Dr. Bakris’ profound impact on our community. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. To apply, click here or go to www.cardiometabolichealth.org/george-bakris-scholarship-program/ NEW!
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
ObjectiveMitochondrial dysfunction is associated with increased risk of atherosclerosis by disrupting key cellular processes that contribute to premature vascular ageing. EOCAD patients had lower mtDNA-CN (p<0.001) and higher mtDNA4977 deletion (p=0.026).
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Tirzepatide’s Dual Benefits in Obesity : Recent studies on tirzepatide , a GLP-1 receptor agonist, revealed significant weight loss and improved outcomes in sleep apnea patients.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content